The ºÚÁÏÉç recently updated its Ketamine Administration via Intramuscular, Oral, Sublingual, and Intranasal Routes as Treatment for Mental Health Conditions and Chronic Pain in the Community Setting interim guidance and published a new Repetitive Transcranial Magnetic Stimulation (rTMS) interim guidance.
What is interim guidance?
Interim guidance sets out or clarifies the ºÚÁÏÉç’s position on an emerging issue or topic. It is intended as guidance for registrants in areas where research and current practice are evolving or changing rapidly, the implementation of processes and procedures may be premature, or it is timely to communicate the ºÚÁÏÉç’s stance on an issue before a practice standard or professional guideline is developed.
Ketamine Administration via Intramuscular, Oral, Sublingual, and Intranasal Routes as Treatment for Mental Health Conditions and Chronic Pain in the Community Setting
The Ketamine Administration via Intramuscular, Oral, Sublingual, and Intranasal Routes as Treatment for Mental Health Conditions and Chronic Pain in the Community Setting interim guidance was revised to highlight the ºÚÁÏÉç’s expectation that registrants:
- ensure that informed consent is obtained from the patient in accordance with the Consent to Treatment practice standard,
- must only recommend treatment when it is justified by the patient’s condition and is in the patient’s best interest,
- communicate and set fees clearly and fairly (as ketamine assisted therapy is currently an uninsured service), and
- ensure they are acting in accordance with the ºÚÁÏÉç’s Advertising and Communication with the Public practice standard.
Repetitive Transcranial Magnetic Stimulation (rTMS)
The ºÚÁÏÉç has received inquiries from registrants regarding the provision of repetitive transcranial magnetic stimulation (rTMS) for the treatment of psychiatric and neurological disorders in adults.
The Repetitive Transcranial Magnetic Stimulation (rTMS) interim guidance was published to clarify the ºÚÁÏÉç’s position on scope of practice and education requirements for registrants who choose to provide this treatment, as well as expectations for delivery of the treatment.